Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization
<p>Abstract</p> <p>Background/Aims</p> <p>Alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) have been used as diagnostic tools for hepatocellular carcinoma (HCC). However, prediction of outcome using AFP and DCP has not been elucidated. We investigated the...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2013-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://www.biomedcentral.com/1471-2407/13/5 |
| _version_ | 1818757235182927872 |
|---|---|
| author | Lee Yong Kang Kim Seung Up Kim Do Young Ahn Sang Hoon Lee Kwang Hun Lee Do Yun Han Kwang-Hyub Chon Chae Yoon Park Jun Yong |
| author_facet | Lee Yong Kang Kim Seung Up Kim Do Young Ahn Sang Hoon Lee Kwang Hun Lee Do Yun Han Kwang-Hyub Chon Chae Yoon Park Jun Yong |
| author_sort | Lee Yong Kang |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background/Aims</p> <p>Alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) have been used as diagnostic tools for hepatocellular carcinoma (HCC). However, prediction of outcome using AFP and DCP has not been elucidated. We investigated the clinical role of AFP and DCP as predictors of treatment outcome in patients with HCC undergoing trans-arterial chemoembolization (TACE).</p> <p>Methods</p> <p>Between January 2003 and December 2005, we enrolled 115 treatment-naïve patients who received TACE as an initial treatment modality. An AFP or DCP response was defined as a reduction of more than 50% from the baseline level 1 month after TACE. Patients with AFP < 20 ng/mL or DCP < 20 mAU/mL were excluded.</p> <p>Results</p> <p>The median age was 59 years and the male gender predominated (<it>n</it> = 81, 70.4%). AFP and DCP response was identified in 91 (79.1%) and 77 (66.9%) patients after TACE. Although progression-free survival (PFS) did not differ according to AFP response (<it>P</it> = 0.150), AFP responders showed significantly better overall survival (OS) than non-responders (34.9 <it>vs.</it> 13.2 months; <it>P</it> = 0.002). In contrast, DCP response did not influence either PFS or OS (all <it>P</it> > 0.05). Multivariate analyses showed that gamma-glutamyltranspeptidase and baseline AFP were predictors of PFS (all <it>P</it> < 0.05) and that male gender, the presence of liver cirrhosis, baseline DCP, number of measurable tumors and AFP response were independent predictors of OS (all <it>P</it> < 0.05).</p> <p>Conclusions</p> <p>AFP response and higher baseline DCP level are significant predictors of OS in treatment-naïve patients with HCC receiving TACE who showed pretreatment elevation of both AFP and DCP.</p> |
| first_indexed | 2024-12-18T06:07:42Z |
| format | Article |
| id | doaj.art-f372a757f0b54650a43e7081bab485b3 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-18T06:07:42Z |
| publishDate | 2013-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-f372a757f0b54650a43e7081bab485b32022-12-21T21:18:30ZengBMCBMC Cancer1471-24072013-01-01131510.1186/1471-2407-13-5Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolizationLee Yong KangKim Seung UpKim Do YoungAhn Sang HoonLee Kwang HunLee Do YunHan Kwang-HyubChon Chae YoonPark Jun Yong<p>Abstract</p> <p>Background/Aims</p> <p>Alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) have been used as diagnostic tools for hepatocellular carcinoma (HCC). However, prediction of outcome using AFP and DCP has not been elucidated. We investigated the clinical role of AFP and DCP as predictors of treatment outcome in patients with HCC undergoing trans-arterial chemoembolization (TACE).</p> <p>Methods</p> <p>Between January 2003 and December 2005, we enrolled 115 treatment-naïve patients who received TACE as an initial treatment modality. An AFP or DCP response was defined as a reduction of more than 50% from the baseline level 1 month after TACE. Patients with AFP < 20 ng/mL or DCP < 20 mAU/mL were excluded.</p> <p>Results</p> <p>The median age was 59 years and the male gender predominated (<it>n</it> = 81, 70.4%). AFP and DCP response was identified in 91 (79.1%) and 77 (66.9%) patients after TACE. Although progression-free survival (PFS) did not differ according to AFP response (<it>P</it> = 0.150), AFP responders showed significantly better overall survival (OS) than non-responders (34.9 <it>vs.</it> 13.2 months; <it>P</it> = 0.002). In contrast, DCP response did not influence either PFS or OS (all <it>P</it> > 0.05). Multivariate analyses showed that gamma-glutamyltranspeptidase and baseline AFP were predictors of PFS (all <it>P</it> < 0.05) and that male gender, the presence of liver cirrhosis, baseline DCP, number of measurable tumors and AFP response were independent predictors of OS (all <it>P</it> < 0.05).</p> <p>Conclusions</p> <p>AFP response and higher baseline DCP level are significant predictors of OS in treatment-naïve patients with HCC receiving TACE who showed pretreatment elevation of both AFP and DCP.</p>http://www.biomedcentral.com/1471-2407/13/5Alpha-fetoproteinDes gamma carboxy prothrombinTransarterial chemoembolizationTumor marker responseHepatocellular carcinomaPrognosisSurvival |
| spellingShingle | Lee Yong Kang Kim Seung Up Kim Do Young Ahn Sang Hoon Lee Kwang Hun Lee Do Yun Han Kwang-Hyub Chon Chae Yoon Park Jun Yong Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization BMC Cancer Alpha-fetoprotein Des gamma carboxy prothrombin Transarterial chemoembolization Tumor marker response Hepatocellular carcinoma Prognosis Survival |
| title | Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization |
| title_full | Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization |
| title_fullStr | Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization |
| title_full_unstemmed | Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization |
| title_short | Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization |
| title_sort | prognostic value of α fetoprotein and des γ carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization |
| topic | Alpha-fetoprotein Des gamma carboxy prothrombin Transarterial chemoembolization Tumor marker response Hepatocellular carcinoma Prognosis Survival |
| url | http://www.biomedcentral.com/1471-2407/13/5 |
| work_keys_str_mv | AT leeyongkang prognosticvalueofafetoproteinanddesgcarboxyprothrombinresponsesinpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolization AT kimseungup prognosticvalueofafetoproteinanddesgcarboxyprothrombinresponsesinpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolization AT kimdoyoung prognosticvalueofafetoproteinanddesgcarboxyprothrombinresponsesinpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolization AT ahnsanghoon prognosticvalueofafetoproteinanddesgcarboxyprothrombinresponsesinpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolization AT leekwanghun prognosticvalueofafetoproteinanddesgcarboxyprothrombinresponsesinpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolization AT leedoyun prognosticvalueofafetoproteinanddesgcarboxyprothrombinresponsesinpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolization AT hankwanghyub prognosticvalueofafetoproteinanddesgcarboxyprothrombinresponsesinpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolization AT chonchaeyoon prognosticvalueofafetoproteinanddesgcarboxyprothrombinresponsesinpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolization AT parkjunyong prognosticvalueofafetoproteinanddesgcarboxyprothrombinresponsesinpatientswithhepatocellularcarcinomatreatedwithtransarterialchemoembolization |